Entrada Therapeutics (TRDA)
(Delayed Data from NSDQ)
$14.75 USD
-1.21 (-7.58%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $14.77 +0.02 (0.14%) 7:58 PM ET
1-Strong Buy of 5 1
B Value A Growth B Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TRDA 14.75 -1.21(-7.58%)
Will TRDA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TRDA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRDA
Bausch Health (BHC) Q2 Earnings In Line, Xifaxan Boosts Sales
Perrigo (PRGO) Beats on Q2 Earnings, Lags Sales, Cuts View
TRDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Moderna (MRNA) Q2 Earnings Beat, Stock Down on Guidance Slash
JAZZ Tops Q2 Earnings & Sales Estimates, Revises '24 View
United Therapeutics (UTHR) Q2 Earnings Lag, Sales Top Estimates
Other News for TRDA
REGENXBIO releases new data on DMD drug ahead of earnings
PepGen stock tumbles 25% following release of DMD drug data
Commit To Buy Entrada Therapeutics At $12.50, Earn 55.6% Annualized Using Options
Entrada Therapeutics’ ENTR-601-44 Shows Promising Phase 1 Results for DMD, Earns Buy Rating
Entrada Therapeutics price target lowered by $2 at H.C. Wainwright, here's why